SCHEMBL19852984

SCHEMBL19852984

O=S(=O)(Nc1cc(Cl)cc2ccncc12)c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.52
▸ CCR9 P51686 1/20 0.48
▸ SLC40A1 Q9NP59 2/20 0.48
▸ CCR2 P41597 4/20 0.48
▸ HTR1A P08908 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ HTR7 P34969 1/20 0.47
▸ HTR6 P50406 1/20 0.47
▸ CYP19A1 P11511 1/20 0.47
▸ CCR1 P32246 1/20 0.46
▸ CCR4 P51679 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ PIK3CA P42336 1/20 0.45
▸ CES1 P23141 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737478 0.89 ALDH1A1 (0.52) ALDH1A1CCR9SLC40A1CCR2HTR1A
SCHEMBL17737476 0.84 ALOX12 (0.62) ALDH1A1CCR9SLC40A1HTR1AHTR2A
SCHEMBL17737362 0.76 IDO1 (0.62) ALDH1A1CCR9SLC40A1HTR1AHTR2A
SCHEMBL17737480 0.75 FFAR4 (0.46) ALDH1A1CCR9SLC40A1CCR2HTR2A
Hydrochloric Acid SCHEMBL20856389 0.72 KDM4E (0.40) ALDH1A1MEN1KMT2AHTT
SCHEMBL17737617 0.70 RECQL (0.69) ALDH1A1SLC40A1ALOX12MEN1KMT2A
SCHEMBL3065621 0.70 CES1 (0.55) ALDH1A1HTR1AHTR2AHTR7HTR6
SCHEMBL5899919 0.70 MCL1 (0.69) ALDH1A1CCR2CYP19A1CES1
SCHEMBL17737677 0.69 RECQL (0.58) ALDH1A1SLC40A1HTR1AHTR2AHTR7
SCHEMBL3064389 0.69 CES1 (0.54) ALDH1A1CYP19A1MEN1KMT2ACES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2018-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE TDO2, IDO2, IDO1 ALDH1A1 3640/4885CCR9 1656/4885SLC40A1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback